Bliss GVS Pharma Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: July 31, 2025, 11:55 am

Market Cap	1,929 Cr.
Current Price	183
High / Low	190/105
Stock P/E	18.1
Book Value	99.7
Dividend Yield	0.26 %
ROCE	11.7 %
ROE	8.36 %
Face Value	1.00
PEG Ratio	4.77

Quick Insight

Bliss GVS Pharma Ltd, trading at ₹154, presents an intriguing investment opportunity within the pharmaceuticals sector, highlighted by a market capitalization of ₹1,621 crore. With a P/E ratio of 19.2, the stock appears reasonably valued, considering its return on equity (ROE) of 8.36% and return on capital employed (ROCE) of 11.7%. The company's operational performance is bolstered by an operating profit margin (OPM) of 11% and a robust interest coverage ratio (ICR) of 25.95x, indicating strong earnings relative to its debt obligations. Notably, with borrowings at a mere ₹88 crore against reserves of ₹1,040 crore, Bliss GVS showcases financial stability. The ownership structure, with promoters holding 35.10% and significant public participation at 44.84%, reflects a balanced stakeholder interest. Given these metrics, investors may find Bliss GVS an appealing option, particularly as it seeks to leverage its solid fundamentals for future growth.

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Bliss GVS Pharma Ltd

Competitors of Bliss GVS Pharma Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Lactose (India) Ltd	141 Cr.	100	247/84.3	27.3	41.7	0.00 %	12.9 %	9.75 %	10.0
MPS Pharmaa Ltd	4.72 Cr.	2.47	4.33/2.47		0.57	0.00 %	9.79 %	59.0 %	10.0
Gujarat Themis Biosyn Ltd	2,663 Cr.	244	390/192	50.6	20.5	0.27 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	37.8 Cr.	51.0	94.9/45.2		8.73	0.00 %	41.4 %	14.6 %	10.0
Gujarat Inject (Kerala) Ltd	32.4 Cr.	22.1	29.1/13.1	31.8	6.83	0.00 %	13.5 %	11.0 %	10.0
Industry Average	19,553.90 Cr	1,224.92		53.83	193.83	0.31%	16.62%	15.26%	6.18

All Competitor Stocks of Bliss GVS Pharma Ltd

Quarterly Result

Metric	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Sales	167	189	172	206	185	160	212	201	198	184	218	210	198
Expenses	147	150	148	158	179	135	158	157	170	149	176	181	177
Operating Profit	20	39	25	48	6	24	54	44	28	34	41	30	21
OPM %	12%	21%	14%	23%	3%	15%	26%	22%	14%	19%	19%	14%	11%
Other Income	12	7	2	6	3	5	13	5	-24	4	5	15	12
Interest	2	2	2	1	5	1	1	2	2	2	4	1	2
Depreciation	4	5	5	5	5	6	6	7	7	7	7	8	8
Profit before tax	26	39	20	47	-1	22	59	40	-4	30	36	36	23
Tax %	11%	30%	21%	37%	-561%	34%	27%	27%	24%	26%	28%	29%	29%
Net Profit	23	27	16	30	3	14	43	29	-5	22	26	26	17
EPS in Rs	1.89	2.48	1.33	2.68	0.32	1.41	4.05	2.64	-0.87	1.97	2.31	2.26	1.47

Last Updated: May 31, 2025, 9:37 am

Below is a detailed analysis of the quarterly data for Bliss GVS Pharma Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

For Sales, as of Mar 2025, the value is 198.00 Cr.. The value appears to be declining and may need further review. It has decreased from 210.00 Cr. (Dec 2024) to 198.00 Cr., marking a decrease of 12.00 Cr..
For Expenses, as of Mar 2025, the value is 177.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 181.00 Cr. (Dec 2024) to 177.00 Cr., marking a decrease of 4.00 Cr..
For Operating Profit, as of Mar 2025, the value is 21.00 Cr.. The value appears to be declining and may need further review. It has decreased from 30.00 Cr. (Dec 2024) to 21.00 Cr., marking a decrease of 9.00 Cr..
For OPM %, as of Mar 2025, the value is 11.00%. The value appears to be declining and may need further review. It has decreased from 14.00% (Dec 2024) to 11.00%, marking a decrease of 3.00%.
For Other Income, as of Mar 2025, the value is 12.00 Cr.. The value appears to be declining and may need further review. It has decreased from 15.00 Cr. (Dec 2024) to 12.00 Cr., marking a decrease of 3.00 Cr..
For Interest, as of Mar 2025, the value is 2.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.00 Cr. (Dec 2024) to 2.00 Cr., marking an increase of 1.00 Cr..
For Depreciation, as of Mar 2025, the value is 8.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 8.00 Cr..
For Profit before tax, as of Mar 2025, the value is 23.00 Cr.. The value appears to be declining and may need further review. It has decreased from 36.00 Cr. (Dec 2024) to 23.00 Cr., marking a decrease of 13.00 Cr..
For Tax %, as of Mar 2025, the value is 29.00%. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 29.00%.
For Net Profit, as of Mar 2025, the value is 17.00 Cr.. The value appears to be declining and may need further review. It has decreased from 26.00 Cr. (Dec 2024) to 17.00 Cr., marking a decrease of 9.00 Cr..
For EPS in Rs, as of Mar 2025, the value is 1.47. The value appears to be declining and may need further review. It has decreased from 2.26 (Dec 2024) to 1.47, marking a decrease of 0.79.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: May 15, 2025, 7:04 am

Metric	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales	345	407	547	798	815	899	689	577	747	752	770	810
Expenses	273	304	391	596	618	739	566	471	629	634	620	683
Operating Profit	71	103	156	203	197	160	123	107	118	117	151	127
OPM %	21%	25%	29%	25%	24%	18%	18%	18%	16%	16%	20%	16%
Other Income	28	20	24	12	-8	35	26	20	-42	18	-0	36
Interest	18	16	19	20	23	4	8	6	5	10	7	8
Depreciation	11	11	13	20	21	9	13	17	17	19	26	29
Profit before tax	71	96	148	175	145	182	129	104	54	106	117	126
Tax %	42%	36%	32%	36%	39%	30%	26%	29%	57%	28%	30%	28%
Net Profit	41	61	100	113	89	127	95	74	23	77	82	90
EPS in Rs	3.97	5.81	8.00	7.95	5.70	11.99	9.43	6.64	1.45	6.80	7.21	8.00
Dividend Payout %	13%	12%	6%	8%	18%	8%	5%	8%	34%	7%	7%	6%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024	2024-2025
YoY Net Profit Growth (%)	48.78%	63.93%	13.00%	-21.24%	42.70%	-25.20%	-22.11%	-68.92%	234.78%	6.49%	9.76%
Change in YoY Net Profit Growth (%)	0.00%	15.15%	-50.93%	-34.24%	63.94%	-67.89%	3.09%	-46.81%	303.70%	-228.29%	3.26%

Bliss GVS Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:	7%
5 Years:	3%
3 Years:	3%
TTM:	5%

Compounded Profit Growth
10 Years:	3%
5 Years:	-4%
3 Years:	44%
TTM:	0%

Stock Price CAGR
10 Years:	-1%
5 Years:	10%
3 Years:	31%
1 Year:	45%

Return on Equity
10 Years:	12%
5 Years:	8%
3 Years:	9%
Last Year:	8%

Last Updated: Unknown

Balance Sheet

Last Updated: July 25, 2025, 3:28 pm

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	10	10	10	10	10	10	10	10	10	10	10	11
Reserves	277	327	402	476	526	636	725	798	808	873	957	1,040
Borrowings	173	160	132	225	118	102	126	122	109	102	100	88
Other Liabilities	123	166	218	311	206	157	168	147	181	171	145	162
Total Liabilities	583	662	762	1,023	860	905	1,030	1,077	1,109	1,157	1,212	1,301
Fixed Assets	213	234	225	305	143	146	242	234	281	379	370	406
CWIP	4	0	9	4	0	47	0	2	22	3	8	21
Investments	0	0	0	0	0	0	0	0	2	8	4	4
Other Assets	365	428	527	714	717	712	788	840	803	768	830	870
Total Assets	583	662	762	1,023	860	905	1,030	1,077	1,109	1,157	1,212	1,301

Below is a detailed analysis of the balance sheet data for Bliss GVS Pharma Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

For Equity Capital, as of Mar 2025, the value is 11.00 Cr.. The value appears strong and on an upward trend. It has increased from 10.00 Cr. (Mar 2024) to 11.00 Cr., marking an increase of 1.00 Cr..
For Reserves, as of Mar 2025, the value is 1,040.00 Cr.. The value appears strong and on an upward trend. It has increased from 957.00 Cr. (Mar 2024) to 1,040.00 Cr., marking an increase of 83.00 Cr..
For Borrowings, as of Mar 2025, the value is 88.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 100.00 Cr. (Mar 2024) to 88.00 Cr., marking a decrease of 12.00 Cr..
For Other Liabilities, as of Mar 2025, the value is 162.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 145.00 Cr. (Mar 2024) to 162.00 Cr., marking an increase of 17.00 Cr..
For Total Liabilities, as of Mar 2025, the value is 1,301.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,212.00 Cr. (Mar 2024) to 1,301.00 Cr., marking an increase of 89.00 Cr..
For Fixed Assets, as of Mar 2025, the value is 406.00 Cr.. The value appears strong and on an upward trend. It has increased from 370.00 Cr. (Mar 2024) to 406.00 Cr., marking an increase of 36.00 Cr..
For CWIP, as of Mar 2025, the value is 21.00 Cr.. The value appears strong and on an upward trend. It has increased from 8.00 Cr. (Mar 2024) to 21.00 Cr., marking an increase of 13.00 Cr..
For Investments, as of Mar 2025, the value is 4.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 4.00 Cr..
For Other Assets, as of Mar 2025, the value is 870.00 Cr.. The value appears strong and on an upward trend. It has increased from 830.00 Cr. (Mar 2024) to 870.00 Cr., marking an increase of 40.00 Cr..
For Total Assets, as of Mar 2025, the value is 1,301.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,212.00 Cr. (Mar 2024) to 1,301.00 Cr., marking an increase of 89.00 Cr..

Notably, the Reserves (1,040.00 Cr.) exceed the Borrowings (88.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Month		Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Cash from Operating Activity +	41	38	113	289	18	40	47	64	135	34	152	106
Cash from Investing Activity +	-11	-29	-50	-249	48	-79	-40	-45	-103	-6	-133	-75
Cash from Financing Activity +	-8	-42	-40	-10	-76	17	-6	-21	-24	-25	-21	-30
Net Cash Flow	22	-34	23	30	-10	-22	0	-2	9	3	-1	0

Free Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Free Cash Flow	-102.00	-57.00	24.00	-22.00	79.00	58.00	-3.00	-15.00	9.00	15.00	51.00	39.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	225	228	222	201	116	134	187	290	293	192	187	192
Inventory Days	58	70	69	55	50	55	46	64	110	116	94	113
Days Payable	212	176	165	153	100	55	47	75	82	86	79	58
Cash Conversion Cycle	71	121	126	102	67	134	186	279	321	221	202	247
Working Capital Days	130	146	160	125	76	182	180	269	319	219	221	232
ROCE %	35%	20%	23%	31%	29%	27%	26%	18%	12%	14%	12%	14%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Promoters	33.14%	34.51%	34.55%	34.46%	35.04%	35.12%	35.06%	34.97%	34.97%	34.90%	34.82%	35.10%
FIIs	17.33%	17.17%	16.68%	16.53%	16.60%	16.50%	16.31%	15.35%	14.74%	13.24%	12.13%	13.51%
DIIs	6.66%	6.65%	6.64%	6.63%	6.63%	6.62%	6.61%	6.60%	6.59%	6.58%	6.56%	6.55%
Public	42.87%	41.67%	42.13%	42.35%	41.73%	41.73%	42.00%	43.08%	43.71%	45.27%	46.49%	44.84%
No. of Shareholders	45,866	46,327	45,753	44,983	43,041	42,182	43,234	40,758	45,157	44,737	52,937	49,558

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
Motilal Oswal S&P BSE Healthcare ETF	669	0.07	0.01	669	2025-04-22 17:25:40	0%

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	1.00	1.00	1.00	1.00	1.00
Basic EPS (Rs.)	7.23	6.83	1.46	6.64	9.43
Diluted EPS (Rs.)	7.11	6.72	1.43	6.49	9.43
Cash EPS (Rs.)	10.31	9.16	3.90	8.84	10.46
Book Value[Excl.RevalReserv]/Share (Rs.)	95.80	88.08	81.64	80.27	72.75
Book Value[Incl.RevalReserv]/Share (Rs.)	95.80	88.08	81.64	80.27	72.75
Revenue From Operations / Share (Rs.)	73.57	72.16	72.09	55.96	66.83
PBDIT / Share (Rs.)	17.13	12.97	14.45	12.30	15.75
PBIT / Share (Rs.)	14.61	11.18	12.78	10.63	14.53
PBT / Share (Rs.)	11.16	10.18	5.22	10.10	12.50
Net Profit / Share (Rs.)	7.79	7.37	2.23	7.17	9.23
NP After MI And SOA / Share (Rs.)	7.21	6.80	1.45	6.64	9.43
PBDIT Margin (%)	23.28	17.97	20.04	21.98	23.57
PBIT Margin (%)	19.86	15.49	17.72	18.99	21.74
PBT Margin (%)	15.17	14.11	7.24	18.03	18.70
Net Profit Margin (%)	10.59	10.20	3.09	12.81	13.81
NP After MI And SOA Margin (%)	9.79	9.42	2.01	11.86	14.11
Return on Networth / Equity (%)	7.80	8.01	1.83	8.47	13.22
Return on Capital Employeed (%)	14.51	12.08	15.13	12.55	18.81
Return On Assets (%)	6.21	6.12	1.35	6.36	9.45
Long Term Debt / Equity (X)	0.03	0.04	0.02	0.04	0.05
Total Debt / Equity (X)	0.09	0.11	0.12	0.12	0.14
Asset Turnover Ratio (%)	0.64	0.53	0.59	0.47	0.50
Current Ratio (X)	5.08	3.61	3.33	3.76	3.33
Quick Ratio (X)	4.34	3.08	2.80	3.27	3.01
Inventory Turnover Ratio (X)	3.06	2.96	3.71	2.73	3.14
Dividend Payout Ratio (NP) (%)	6.90	7.32	34.41	7.52	12.78
Dividend Payout Ratio (CP) (%)	5.11	5.79	15.98	6.01	11.31
Earning Retention Ratio (%)	93.10	92.68	65.59	92.48	87.22
Cash Earning Retention Ratio (%)	94.89	94.21	84.02	93.99	88.69
Interest Coverage Ratio (X)	25.95	13.04	31.60	23.01	21.47
Interest Coverage Ratio (Post Tax) (X)	17.03	8.40	21.40	14.42	15.35
Enterprise Value (Cr.)	1087.33	770.70	752.99	990.81	1054.79
EV / Net Operating Revenue (X)	1.41	1.03	1.01	1.72	1.53
EV / EBITDA (X)	6.06	5.70	5.03	7.81	6.49
MarketCap / Net Operating Revenue (X)	1.53	0.98	1.07	1.76	1.51
Retention Ratios (%)	93.09	92.67	65.58	92.47	87.21
Price / BV (X)	1.22	0.83	0.97	1.26	1.41
Price / Net Operating Revenue (X)	1.53	0.98	1.07	1.76	1.51
EarningsYield	0.06	0.09	0.01	0.06	0.09

After reviewing the key financial ratios for Bliss GVS Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 24, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 1.00.
For Basic EPS (Rs.), as of Mar 24, the value is 7.23. This value is within the healthy range. It has increased from 6.83 (Mar 23) to 7.23, marking an increase of 0.40.
For Diluted EPS (Rs.), as of Mar 24, the value is 7.11. This value is within the healthy range. It has increased from 6.72 (Mar 23) to 7.11, marking an increase of 0.39.
For Cash EPS (Rs.), as of Mar 24, the value is 10.31. This value is within the healthy range. It has increased from 9.16 (Mar 23) to 10.31, marking an increase of 1.15.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 95.80. It has increased from 88.08 (Mar 23) to 95.80, marking an increase of 7.72.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 95.80. It has increased from 88.08 (Mar 23) to 95.80, marking an increase of 7.72.
For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 73.57. It has increased from 72.16 (Mar 23) to 73.57, marking an increase of 1.41.
For PBDIT / Share (Rs.), as of Mar 24, the value is 17.13. This value is within the healthy range. It has increased from 12.97 (Mar 23) to 17.13, marking an increase of 4.16.
For PBIT / Share (Rs.), as of Mar 24, the value is 14.61. This value is within the healthy range. It has increased from 11.18 (Mar 23) to 14.61, marking an increase of 3.43.
For PBT / Share (Rs.), as of Mar 24, the value is 11.16. This value is within the healthy range. It has increased from 10.18 (Mar 23) to 11.16, marking an increase of 0.98.
For Net Profit / Share (Rs.), as of Mar 24, the value is 7.79. This value is within the healthy range. It has increased from 7.37 (Mar 23) to 7.79, marking an increase of 0.42.
For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 7.21. This value is within the healthy range. It has increased from 6.80 (Mar 23) to 7.21, marking an increase of 0.41.
For PBDIT Margin (%), as of Mar 24, the value is 23.28. This value is within the healthy range. It has increased from 17.97 (Mar 23) to 23.28, marking an increase of 5.31.
For PBIT Margin (%), as of Mar 24, the value is 19.86. This value is within the healthy range. It has increased from 15.49 (Mar 23) to 19.86, marking an increase of 4.37.
For PBT Margin (%), as of Mar 24, the value is 15.17. This value is within the healthy range. It has increased from 14.11 (Mar 23) to 15.17, marking an increase of 1.06.
For Net Profit Margin (%), as of Mar 24, the value is 10.59. This value exceeds the healthy maximum of 10. It has increased from 10.20 (Mar 23) to 10.59, marking an increase of 0.39.
For NP After MI And SOA Margin (%), as of Mar 24, the value is 9.79. This value is within the healthy range. It has increased from 9.42 (Mar 23) to 9.79, marking an increase of 0.37.
For Return on Networth / Equity (%), as of Mar 24, the value is 7.80. This value is below the healthy minimum of 15. It has decreased from 8.01 (Mar 23) to 7.80, marking a decrease of 0.21.
For Return on Capital Employeed (%), as of Mar 24, the value is 14.51. This value is within the healthy range. It has increased from 12.08 (Mar 23) to 14.51, marking an increase of 2.43.
For Return On Assets (%), as of Mar 24, the value is 6.21. This value is within the healthy range. It has increased from 6.12 (Mar 23) to 6.21, marking an increase of 0.09.
For Long Term Debt / Equity (X), as of Mar 24, the value is 0.03. This value is below the healthy minimum of 0.2. It has decreased from 0.04 (Mar 23) to 0.03, marking a decrease of 0.01.
For Total Debt / Equity (X), as of Mar 24, the value is 0.09. This value is within the healthy range. It has decreased from 0.11 (Mar 23) to 0.09, marking a decrease of 0.02.
For Asset Turnover Ratio (%), as of Mar 24, the value is 0.64. It has increased from 0.53 (Mar 23) to 0.64, marking an increase of 0.11.
For Current Ratio (X), as of Mar 24, the value is 5.08. This value exceeds the healthy maximum of 3. It has increased from 3.61 (Mar 23) to 5.08, marking an increase of 1.47.
For Quick Ratio (X), as of Mar 24, the value is 4.34. This value exceeds the healthy maximum of 2. It has increased from 3.08 (Mar 23) to 4.34, marking an increase of 1.26.
For Inventory Turnover Ratio (X), as of Mar 24, the value is 3.06. This value is below the healthy minimum of 4. It has increased from 2.96 (Mar 23) to 3.06, marking an increase of 0.10.
For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 6.90. This value is below the healthy minimum of 20. It has decreased from 7.32 (Mar 23) to 6.90, marking a decrease of 0.42.
For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 5.11. This value is below the healthy minimum of 20. It has decreased from 5.79 (Mar 23) to 5.11, marking a decrease of 0.68.
For Earning Retention Ratio (%), as of Mar 24, the value is 93.10. This value exceeds the healthy maximum of 70. It has increased from 92.68 (Mar 23) to 93.10, marking an increase of 0.42.
For Cash Earning Retention Ratio (%), as of Mar 24, the value is 94.89. This value exceeds the healthy maximum of 70. It has increased from 94.21 (Mar 23) to 94.89, marking an increase of 0.68.
For Interest Coverage Ratio (X), as of Mar 24, the value is 25.95. This value is within the healthy range. It has increased from 13.04 (Mar 23) to 25.95, marking an increase of 12.91.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 17.03. This value is within the healthy range. It has increased from 8.40 (Mar 23) to 17.03, marking an increase of 8.63.
For Enterprise Value (Cr.), as of Mar 24, the value is 1,087.33. It has increased from 770.70 (Mar 23) to 1,087.33, marking an increase of 316.63.
For EV / Net Operating Revenue (X), as of Mar 24, the value is 1.41. This value is within the healthy range. It has increased from 1.03 (Mar 23) to 1.41, marking an increase of 0.38.
For EV / EBITDA (X), as of Mar 24, the value is 6.06. This value is within the healthy range. It has increased from 5.70 (Mar 23) to 6.06, marking an increase of 0.36.
For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 1.53. This value is within the healthy range. It has increased from 0.98 (Mar 23) to 1.53, marking an increase of 0.55.
For Retention Ratios (%), as of Mar 24, the value is 93.09. This value exceeds the healthy maximum of 70. It has increased from 92.67 (Mar 23) to 93.09, marking an increase of 0.42.
For Price / BV (X), as of Mar 24, the value is 1.22. This value is within the healthy range. It has increased from 0.83 (Mar 23) to 1.22, marking an increase of 0.39.
For Price / Net Operating Revenue (X), as of Mar 24, the value is 1.53. This value is within the healthy range. It has increased from 0.98 (Mar 23) to 1.53, marking an increase of 0.55.
For EarningsYield, as of Mar 24, the value is 0.06. This value is below the healthy minimum of 5. It has decreased from 0.09 (Mar 23) to 0.06, marking a decrease of 0.03.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Bliss GVS Pharma Ltd as of July 31, 2025 is: 121.00

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of July 31, 2025, Bliss GVS Pharma Ltd is Overvalued by 33.88% compared to the current share price 183.00

Intrinsic Value of Bliss GVS Pharma Ltd as of July 31, 2025 is: 125.59

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of July 31, 2025, Bliss GVS Pharma Ltd is Overvalued by 31.37% compared to the current share price 183.00

Last 5 Year EPS CAGR: 3.80%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a high average ROCE of 21.75%, which is a positive sign. The company has higher reserves (653.75 cr) compared to borrowings (129.75 cr), indicating strong financial stability. The company has shown consistent growth in sales (679.67 cr) and profit (121.08 cr) over the years.	The stock has a high average Working Capital Days of 188.25, which may not be favorable. The stock has a high average Cash Conversion Cycle of 173.08, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Bliss GVS Pharma Ltd:
1. Net Profit Margin: 10.59%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 14.51% (Industry Average ROCE: 16.62%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 7.8% (Industry Average ROE: 15.26%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 17.03
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 4.34
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 18.1 (Industry average Stock P/E: 53.83)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.09
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Bliss GVS Pharma Ltd. is a Public Limited Listed company incorporated on 11/12/1984 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24230MH1984PLC034771 and registration number is 034771. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company's Total Operating Revenue is Rs. 667.20 Cr. and Equity Capital is Rs. 10.54 Cr. for the Year ended 31/03/2025.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	102, Hyde Park, Saki Vihar Road, Mumbai Maharashtra 400072	info@blissgvs.com http://www.blissgvs.com

Management
Name	Position Held
Mr. Nandkumar K Chodankar	Chairman & Ind.Director
Mr. Gagan Harsh Sharma	Managing Director
Dr. Vibha Gagan Sharma	Whole Time Director
Mrs. Shruti Vishal Rao	Whole Time Director
Mr. Santosh L Parab	Independent Director
Ms. Shilpa Bhatia	Independent Woman Director

FAQ

What is the intrinsic value of Bliss GVS Pharma Ltd?

Bliss GVS Pharma Ltd's intrinsic value (as of 31 July 2025) is 121.00 33.88% lower the current market price of 183.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 1,929 Cr. market cap, FY2025-2026 high/low of 190/105, reserves of 1,040 Cr, and liabilities of 1,301 Cr.

What is the Market Cap of Bliss GVS Pharma Ltd?

The Market Cap of Bliss GVS Pharma Ltd is 1,929 Cr..

What is the current Stock Price of Bliss GVS Pharma Ltd as on 31 July 2025?

The current stock price of Bliss GVS Pharma Ltd as on 31 July 2025 is 183.

What is the High / Low of Bliss GVS Pharma Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Bliss GVS Pharma Ltd stocks is ₹190/105.

What is the Stock P/E of Bliss GVS Pharma Ltd?

The Stock P/E of Bliss GVS Pharma Ltd is 18.1.

What is the Book Value of Bliss GVS Pharma Ltd?

The Book Value of Bliss GVS Pharma Ltd is 99.7.

What is the Dividend Yield of Bliss GVS Pharma Ltd?

The Dividend Yield of Bliss GVS Pharma Ltd is 0.26 %.

What is the ROCE of Bliss GVS Pharma Ltd?

The ROCE of Bliss GVS Pharma Ltd is 11.7 %.

What is the ROE of Bliss GVS Pharma Ltd?

The ROE of Bliss GVS Pharma Ltd is 8.36 %.

What is the Face Value of Bliss GVS Pharma Ltd?

The Face Value of Bliss GVS Pharma Ltd is 1.00.